Editorial Commentary
It’s far better to be alone than to be in bad company
Abstract
Somatic KRAS mutations are the most common oncogenic alterations detected in non-small cell lung cancer (NSCLC), accounting for 25% of the cases (1). Clinical course of KRAS-mutant NSCLC is very heterogenous, suggesting an underlying biological complexity that is not comprehensively understood.
